The U.S. Food and Drug Administration (FDA) held a two-day public meeting to discuss managing the potential side effects of gene therapies following the death of a boy with a rare neuromuscular disease. High doses of gene therapies are known to cause liver damage, and recent studies have also found a potential long-term cancer risk […]
Messenger RNA (mRNA) is in the spotlight right now as the basis of the Moderna and Pfizer/BioNTech vaccines for COVID-19. Thanks to this newfound prominence, its profile has been raised as a powerful tool in cancer research as well. As a courier of genetic information and protein assembler, mRNA can tell scientists which genes are […]
The FDA announced a trial hold after two participants with sickle cell disease (SCD) in the LentiGlobin gene therapy trials developed AML and MDS. According to bluebird bio, the manufacturer of LentiGlobin products, the company was unable to find any cancer cells in the patient’s bone marrow and has asked the FDA for permission to […]
How can oncologists successfully implement precision medicine strategies in diffuse large B-cell lymphoma (DLBCL)? In this review, the authors describe the recently proposed genomic categories of DLBCL and their potential use for personalized treatment, as well as the significant challenges they will present.
Based on the results of an open-label trial, selpercatinib (Retevmo) becomes the first targeted therapy to be granted accelerated approval by the FDA for use in patients with cancer who have certain tumors that have an alteration (mutation or fusion) in the RET gene.